Investigation of the effect of N-acetylcysteine on serum levels of oxidative inflammatory biomarkers in patients with stroke

Abstract Background N -acetylcysteine (NAC) is a tolerable and safe drug capable of reducing free radicals other oxidants. We included 74 individuals with ischemic stroke in this randomized, single-blind clinical trial placed them into intervention ( n = 37) control groups. In the group, addition to standard treatment for stroke, they received NAC at dose 100 mg/kg bolus then 10 mg/kg/h h. The group only treatment. Blood samples were taken before starting 24 h after receiving measure catalase, paraoxonase, malondialdehyde (MDA), neopterin, total antioxidant capacity (TAC), oxidant status (TOS) parameters. National Institutes Health Stroke Scale (NIHSS) was also calculated h, 2 weeks, 1 month, 3 months drug. Results There no significant difference between results parameters group; however, could significantly reduce TOS P 0.02) group. Moreover, administration notably decrease NIHSS each time point when compared After subgrouping increase catalase < 0.001), paraoxonase TAC 0.001) while decreased MDA neopterin intervention-responding subgroup monitored point. Conclusion can be promising as complementary powerful oxidative stress improving cognitive function stroke.